title: [Hyperhomocysteinemia in chronic renal failure.].
abstract: Chronic renal failure (CRF) is frequently associated with increased plasma levels of homocysteine (Hcy), an amino acid that can be considered a new uremic toxin according to recent evidence. Studies on Hcy described first homocystinuria, an inherited disease characterized by high plasma Hcy levels and premature cardiovascular disease, resulting in high mortal-ity rates. Hyperhomocysteinemia was then shown to be associated with cardiovascular events both in the general population and in CRF patients. Hcy is a sulfur amino acid derived from dietary methionine, an essential amino acid. Methionine is condensed with ATP to form S-adenosylmethionine (AdoMet), the universal methyl donor in transmethylation reactions. The AdoMet demethylated product is S-adenosylhomocysteine (AdoHcy), which is the direct precursor of Hcy in vivo. Hcy is toxic for the endothelium, it enhances vascular smooth muscle cell proliferation, increases platelet aggregation, and acts on the coagulation cascade and fibrinolysis. Several mechanisms have been discussed to explain Hcy toxicity. Hcy levels increase as renal function declines and progresses to ESRD; the causes of hyperhomocysteinemia are still unclear. Studies in humans show that renal metabolic extraction depends on renal plasma flow; in addition, an alteration of the extrarenal metabolic clearance, depending on uremic toxins, may occur. Among the consequences of hyperhomocysteinemia in renal failure are: impaired protein methylation, with altered protein repair processes; DNA hypomethylation, with an alteration in the allelic expression of genes regulated through methylation; and protein homocysteinylation. Further, this review is dealing with the 'reverse epidemiology' issue, outlining also the main Hcy-lowering strategies.
authors.affiliation: I Divisione di Nefrologia, II Università degli Studi (SUN), Napoli - Italy.
authors.forename: E
authors.initials: E
authors.lastname: Satta
authors.forename: A F
authors.initials: AF
authors.lastname: Perna
authors.forename: C
authors.initials: C
authors.lastname: Lombardi
authors.forename: F
authors.initials: F
authors.lastname: Acanfora
authors.forename: E
authors.initials: E
authors.lastname: Violetti
authors.forename: M M
authors.initials: MM
authors.lastname: Romano
authors.forename: R
authors.initials: R
authors.lastname: Capasso
authors.forename: M
authors.initials: M
authors.lastname: Pisano
authors.forename: F
authors.initials: F
authors.lastname: Paduano
authors.forename: N G
authors.initials: NG
authors.lastname: De Santo
mesh_terms: D006710:Homocysteine / Q000378:metabolism; D006712:Homocystinuria / Q000209:etiology; D006801:Humans; D020138:Hyperhomocysteinemia / Q000209:etiology* / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000378:metabolism; D014511:Uremia / Q000150:complications
chemical_list: D006710:Homocysteine